Clearmind Medicine (NASDAQ:CMND – Get Free Report) and Context Therapeutics (NASDAQ:CNTX – Get Free Report) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their valuation, risk, analyst recommendations, profitability, institutional ownership, dividends and earnings.
Earnings and Valuation
This table compares Clearmind Medicine and Context Therapeutics”s gross revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Clearmind Medicine | N/A | N/A | -$3.86 million | ($19.72) | -0.04 |
| Context Therapeutics | N/A | N/A | -$36.12 million | ($0.38) | -6.82 |
Institutional & Insider Ownership
96.1% of Clearmind Medicine shares are owned by institutional investors. Comparatively, 14.0% of Context Therapeutics shares are owned by institutional investors. 3.0% of Context Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.
Analyst Ratings
This is a summary of current ratings and recommmendations for Clearmind Medicine and Context Therapeutics, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Clearmind Medicine | 0 | 0 | 0 | 0 | 0.00 |
| Context Therapeutics | 1 | 0 | 7 | 1 | 2.89 |
Context Therapeutics has a consensus price target of $6.60, suggesting a potential upside of 154.83%. Given Context Therapeutics’ stronger consensus rating and higher probable upside, analysts clearly believe Context Therapeutics is more favorable than Clearmind Medicine.
Volatility & Risk
Clearmind Medicine has a beta of 1.51, suggesting that its stock price is 51% more volatile than the S&P 500. Comparatively, Context Therapeutics has a beta of 1.97, suggesting that its stock price is 97% more volatile than the S&P 500.
Profitability
This table compares Clearmind Medicine and Context Therapeutics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Clearmind Medicine | N/A | -207.53% | -100.70% |
| Context Therapeutics | N/A | -47.04% | -44.08% |
Summary
Context Therapeutics beats Clearmind Medicine on 9 of the 12 factors compared between the two stocks.
About Clearmind Medicine
Clearmind Medicine Inc., a clinical pharmaceutical company, develops novel psychedelic medicines to treat under-served health problems in Canada and internationally. It develops treatments for alcohol use disorders, mental health disorder, binge drinking, obesity and metabolic disorder, and eating disorders, as well as depression, binge eating, psychotherapy, and other addiction and binge behaviors. The company also develops MEAI compound which is in IND-enabling study for the treatment of alcohol use disorder; and is in pre-clinical study for treatment of obesity, weight loss, metabolic disorder, and addiction. In addition, it has a collaboration with SciSparc Ltd. to conduct a study evaluating the companies combination treatment for obesity and metabolic syndrome; and with Yissum Research Development Company of the Hebrew University of Jerusalem for the discovery and development of novel psychedelic-derived therapeutics to treat mental disorders. The company was formerly known as Cyntar Ventures Inc. and changed its name to Clearmind Medicine Inc. in March 2021. Clearmind Medicine Inc. was incorporated in 2017 and is based in Vancouver, Canada.
About Context Therapeutics
Context Therapeutics Inc., a biopharmaceutical company, develops products for the treatment of solid tumors. Its lead program candidate is CTIM-76, an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6. The company has a collaboration and licensing agreement with Integral Molecular, Inc. for the development of a CLDN6 bispecific monoclonal antibody for cancer therapy. Context Therapeutics Inc. was incorporated in 2015 and is headquartered in Philadelphia, Pennsylvania.
Receive News & Ratings for Clearmind Medicine Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Clearmind Medicine and related companies with MarketBeat.com's FREE daily email newsletter.
